Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2016

View Archived Issues

Abeona signs exclusive license for UNC's gene therapy portfolio

Entasis Therapeutics reports data from phase II study of EXT-0914

Cidara Therapeutics selects candidate from immunotherapy discovery platform

The Medicines Company enters strategic partnership with BARDA to develop new antibiotics

NIH grant supports Feinstein Institute's research into autism spectrum disorders

SAR-342434 is as efficacious as insulin lispro in T1DM patients

Bronchiolitis obliterans model created to test reparative effect of stem cell transplantation

PharmaMar submits MAA to EMA for Aplidin

Tocagen enrolls first patient in phase Ib for vocimagene amiretrorepvec

Phase IIb results for the GMZ-2 malaria vaccine in African children

Teva Pharmaceutical Industries reports positive results in phase III trial of SD-809

Curemark initiates enrollment for phase III trial evaluating CM-AT in autism

H. Lundbeck's phase III trial of idalopirdine does not meet primary endpoint

Selexis expands collaboration with IAVI

Phase I results encourage further exploration of ABT-555 in multiple sclerosis

Safety review committee supports continuation of Betalutin trial at higher dose

EMA premature in notification of SomaKit TOC opinion

New zebrafish model displays features of 21-hydroxylase deficiency

FDA grants fast track designation to PfSPZ vaccine

Promising phase III data on Zykadia in untreated patients with ALK-positive NSCLC

Phase IIa osteoarthritis study of MIV-711 recommended to continue

Daiichi Sankyo seeks Japanese approval for Pralia in rheumatoid arthritis

Genfit validates RORgammat inverse agonist drug candidates for pre-IND studies

Astellas Pharma and Kotobuki Pharmaceutical patent agents for nocturia

Pharmakea describes LOXL2 inhibitors

Alpharmagen patents nicotinic acetylcholine alpha7 receptor positive allosteric modulators

Dana-Farber Cancer Institute reports MELK inhibitors

GlaxoSmithKline prepares and tests bromodomain-containing protein inhibitors